Byondis B.V.: Byondis Initiates Phase I Study of Next Generation Antibody-Drug Conjugate BYON3521

BYON3521 Targets c-MET, Widely Overexpressed in Solid TumorsTherapy Uses Proprietary Technologies Designed to Enhance Efficacy and SafetyNIJMEGEN, Netherlands, Aug. 25, 2022 /PRNewswire/ --

Related Keywords

Italy ,Netherlands ,Nijmegen ,Gelderland ,Belgium ,Dutch ,Prnewswire Byondis ,Kostenloser Wertpapierhandel ,Wim Dokter ,Jan Schellens ,Us Food Drug Administration ,European Medicines Agency ,Conjugation Technology ,Widely Overexpressed ,Uses Proprietary Technologies Designed ,Enhance Efficacy ,Human Dose Escalation ,Expansion Trial With ,Antibody Drug Conjugate ,Expressing Locally Advanced ,Metastatic Solid ,Byondis Chief Medical Officer Jan Schellens ,Byondis Chief Scientific Officer Wim Dokter ,Biologics License Application ,Drug Administration ,Marketing Authorization Application ,Dose Escalation ,Maximum Tolerated Dose ,Recommended Dose ,Next Generation Antibody Drug ,Proprietary Linker Drug ,Site Specific Conjugation ,Good Manufacturing Practice ,Byondis ,Nitiates ,Hase ,Study ,Text ,Generation ,Ntibody ,Drug ,Conjugate ,Yon3521 ,